Answers are grounded in this paper and cite their sources.
Epstein–Barr virus (EBV) is a nearly ubiquitous oncogenic virus that drives the development of post-transplant lymphoproliferative disorder (PTLD) in solid organ-transplant (SOT) recipients through B-lymphocyte infection and disruption of normal apoptotic and immune-surveillance pathways. This review synthesizes current evidence on the relationship between EBV DNAemia and PTLD, demonstrating that elevated whole blood or plasma EBV viral loads may precede and help identify patients at increased risk of EBV+ PTLD, though testing methodology and timing remain unstandardized across studies. EBV DNAemia is associated with increased risk of PTLD, particularly in high-risk serostatus and heavily immunosuppressed recipients. However, differences in specimen types, assay methodologies, and intervention thresholds currently limit predictive precision and standardization of preemptive management. Frontline management of EBV DNAemia follows a stepwise approach beginning with reduced immunosuppression, escalating to rituximab and sequential chemoimmunotherapy as needed if PTLD develops. For relapsed or refractory EBV-positive disease, emerging EBV-directed cellular therapies show meaningful survival benefit over historical outcomes. Novel biomarkers for EBV may include soluble ZEBRA protein assessment, EBV DNA methylation, and LMP1 mutation status, in addition to CMV DNAemia. There remains an urgent unmet need for standardized, prospective, multicenter studies to define optimal EBV monitoring strategies and guide preemptive intervention in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Duarte et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: